Drug intelligence / Profile preview

NTCB01-1

Development stage: Phase 3
Lead developer: Yuhan
Administration: Parenteral

Overview

NTCB01-1 is an investigational product developed by Yuhan Corp. It is being evaluated as a dietary supplement for patients who require parenteral nutrition, with its highest development phase being Phase 3 clinical trials. The precise composition, mechanism of action, and modality are not publicly disclosed. The drug is intended to support nutritional needs in patients unable to receive adequate nutrition via the gastrointestinal tract[1][2][3].

Beyond the preview

Go deeper on NTCB01-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTCB01-1.

Explore the full profile